Clinical trials: Head and Neck Cancer Metastatic
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancers who are receiving FOLFOX regimen with or without bevacizumab.
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8
- Trial name
- NCT04164069
- Testing
- Bevacizumab, Dasatinib, Fluorouracil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Anne Noonan
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
This is an open-label, randomized, phase II trial to test the efficacy of Ibrutinib in combination with either Nivolumab or Cetuximab in the treatment of recurrent and/or metastatic head an neck squamous cell carcinoma
- Trial name
- NCT03646461
- Testing
- Ibrutinib 560mg PO daily (Imbruvica), Cetuximab, Nivolumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Esophageal Squamous Cell Carcinoma
A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a prospective, single-arm, open-label，multi-center, phase Ib/II study, aiming to evaluate the efficacy and safety of Fruquintinib combined With Cadonilimab (AK104) and Tegafur，Gimeracil and Oteracil Potassium in patients…
- Trial name
- NCT06487702
- Testing
- fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Rui-hua Xu, MD, PhD
Head and Neck Cancer
Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab
Primary Objective: To assess the overall response rate (complete and partial response) to Abraxane in patients with recurrent or metastatic head and neck cancer with the addition of Cetuximab on disease progression.
- Trial name
- NCT00319839
- Testing
- Abraxane, Cetuximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Irvine
Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
Increased fibroblast activation protein expression is positively correlated with the dedifferentiation and aggressiveness of thyroid cancer.
- Conditions
- Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma
- Trial name
- NCT05410821
- Testing
- 177Lu-DOTA-EB-FAPI 1 radionuclide therapy, 177Lu-DOTA-EB-FAPI 2 radionuclide therapy, 177Lu-DOTA-EB-FAPI 3 radionuclide therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Multiple Indications Cancer
Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico
This is a post-marketing study of patients who started nivolumab as first- or second-line therapy for metastatic melanoma or as second-line therapy for metastatic squamous non-small cell lung cancer (SqNSCLC) , metastatic…
- Trial name
- NCT03161613
- Testing
- Non-Interventional
- Where
- Mexico
- Sponsor
- Bristol-Myers Squibb
Squamous Cell Carcinoma of Oral Cavity
Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+
Primary Objective: To determine the 2-year distant failure rate of maintenance tegafur-uracil in patients with squamous cell carcinoma of oral cavity with extracapsular spreading of lymph nodes.
- Trial name
- NCT03121313
- Testing
- tegafur-uracil
- Where
- Taiwan
- Volunteers
- 68 people
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Cancer
Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System
The goal of this clinical research study is to learn if using the PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of the body that has, or is suspected to have cancer will give researchers the same or…
- Trial name
- NCT01030497
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
(I) AI Model for Diagnosing Lymph Node Metastasis We developed an AI model to help diagnose whether a single lymph node in nasopharyngeal cancer has spread. The model uses MRI images of the lymph node and the area around it.
- Trial name
- NPC (NCT06829147)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Salivary Gland Carcinoma, Adenoid Cystic Carcinoma
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary…
- Conditions
- Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Salivary Gland Neoplasms
- Trial name
- NCT04832438
- Testing
- 9-ING-41, Carboplatin
- Where
- United States
- Sponsor
- Actuate Therapeutics Inc.
Squamous Cell Carcinoma of Head and Neck
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
This is a single arm phase II trial to study the efficacy and safety of a Cdk inhibitor P276-00 in the treatment of squamous cell carcinoma of head and neck.
- Trial name
- MONARCH (NCT00824343)
- Testing
- P276-00
- Where
- 9 sites in India
- Volunteers
- 86 people
- Sponsor
- Piramal Enterprises Limited
Gastric Cancer, Pancreas Cancer
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
This prospective, randomized, open-label and multicenter phase III study is aimed to estimate the survival benefit of Early Palliative Care (EPC) combined with standard oncology care including first-line chemotherapy…
- Conditions
- Gastric Cancer, Pancreas Cancer, Bile Duct Cancer, Gastroesophageal Cancer
- Trial name
- EPIC-1511 (NCT02853474)
- Testing
- Early Palliative Care visit, EORTC-QLQ-C30 questionnaire, HADS score
- Where
- 20 sites in France
- Volunteers
- 480 people
- Sponsor
- Centre Oscar Lambret
Recurrent/Metastatic Head and Neck Cancer
Treatment of Recurrent/Metastatic Head and Neck Cancer
This study is a Phase Ib/II study of TQB2922 injection (subcutaneous). In the Phase Ib stage, a 3+3 dose-escalation design was used to determine the RP2D and pharmacokinetic characteristics of TQB2922 injection (subcutaneous)…
- Trial name
- NCT07601204
- Testing
- TQB2922 Subcutaneous Injection
- Where
- 10 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Metastatic Esophageal Squamous Cell Carcinoma
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
- Trial name
- REICRAE (NCT06190652)
- Testing
- Chemotherapy combined with immunotherapy, radiotherapy
- Where
- 5 sites in China
- Volunteers
- 728 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Squamous Cell Carcinoma
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04193293
- Testing
- Duvelisib, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- SecuraBio
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Thyroid Cancer, Thyroid Carcinoma, Papillary
Near-infrared Fluorescence With Indocyanine Green for Identification of Sentinels and Parathyroids During Thyroidectomy
Indocyanine green (ICG) is a water-soluble organic dye that is cleared totally through the hepatobiliary system. It has a half-life of 3-4 mins, which allows repeated applications.
- Conditions
- Thyroid Cancer, Thyroid Carcinoma, Papillary, Thyroid Metastases, Thyroid Neoplasms
- Trial name
- NCT04424485
- Testing
- Total thyroidectomy (TT), Central lymph node dissection (CLND), Sentinel lymph node (SLN) bopsy
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Umraniye Education and Research Hospital
Nasopharyngeal Cancer
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
Cisplatin or Carboplatin will be given on day 1 every 21 days for 6 cycles; Gemcitabine will be given on day 1 and day 8 every 21 days for 6 cycles.
- Trial name
- NCT00603915
- Testing
- Gemcitabine, Carboplatin/Cisplatin, erlotinib
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Toxicity Due to Radiotherapy, Nasopharyngeal Carcinoma
Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal Carcinoma
To determine whether subtractive radiotherapy can significantly reduce the acute side effects of radiotherapy and improve the quality of life of patients on the basis of ensuring the existing curative effect.
- Trial name
- NCT05741008
- Testing
- Target range
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Kunming Medical University
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.